NuSynth AI shrinks R&D cycles for cost-effective manufacturing by turning every experiment into lasting intelligence.
The Bengaluru-based startup just raised Rs 36.5 crore in a seed round co-led by Avaana Capital and Shastra VC to scale its AI-driven chemical synthesis platform.
The system digests experimental data both successful and failed alike into a proprietary knowledge base.
This guides the next round of molecule selection, reaction design, and commercial scale-up. Manufacturers gain faster routes to lower-cost, higher-yield, and more sustainable processes.
NuSynth aims to replace slow, linear trial-and-error with compounding insight that shortens development timelines and cuts dependence on imported intermediates.
NuSynth builds predictive synthesis models that evaluate raw materials, reaction pathways, and process economics in one pass. Its AI engine converts lab results into reusable knowledge so each program starts smarter than the last.
Researchers identify alternative synthesis routes that improve cost, yield, safety, sustainability, and scalability instead of making small tweaks to old methods.
The platform focuses on complex chemistry that India currently imports, especially intermediates for pharmaceuticals and electronics chemicals. Through redesigning the underlying processes, NuSynth delivers superior economics and sustainability for global customers.
Key advantages the AI delivers:
Also Read: Why Contextual Industrial Data Is Critical for AI-Ready Manufacturing in India
NuSynth currently works on four to five molecules and has already developed proprietary reaction technologies that can apply across multiple products.
The team operates an R&D laboratory and pilot plant in Mysuru and is building a second research facility in Bengaluru. A network of more than 20 Indian manufacturing partners stands ready to move validated processes into industrial production.
The company expects to begin commercializing its first proprietary processes in the second half of 2027 after customer sampling and validation batches. Longer-term plans include expanding into nutraceuticals, flavors and fragrances while keeping the same AI-powered approach.
The Rs 36.5 crore will strengthen R&D and technology capabilities, build the initial portfolio of proprietary processes, expand scale-up infrastructure and grow the scientific team.
Co-founder and CEO Poorvank Purohit, former MD and CEO of Solara Active Pharma Sciences, frames the ambition clearly: India has mastered manufacturing established chemistry; the next chapter must innovate the chemistry itself. “We are talking about R&D as a growth engine,” he says.
The founding team also includes Dr Ramesha A R, a former postdoctoral researcher at the National Institutes of Health, along with Abhishek Deo and Dipak Bajaj.
NuSynth positions AI as the engine that turns chemical R&D from a long, costly gamble into a rapid, compounding advantage. Faster cycles, lower costs, and home-grown proprietary processes now move from ambition to funded reality.
We use cookies to ensure you get the best experience on our website. Read more...
